企業プロフィール · Healthcare

ICON PLC

ICLR · 米国株
取引所
米国株
国 / 地域
USA
上場日
1998年5月15日
従業員数
40,100
公式サイト
www.iconplc.com
現在値
$146
リアルタイム · 2026年6月18日
妥当買付価格
≤ $116
安全マージンの起点
ベイリー成長スコア
37/100
やや弱い
本源的価値 · 3 段階レンジ 現在値 $146 リアルタイム · 妥当な本源的価値レンジ内

総合バリュエーションレンジ · 保守的 $108–$116 / 妥当 $145–$185 / 楽観的 $230–$250。$146 時点で 妥当な本源的価値レンジ内。

レポート公開時 $149.04(2026年6月12日)

この銘柄のレポートはお使いの言語でまだありません。

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.

時価総額$109.7億
売上高(TTM)$82.51億
EBITDA$13.95億
純利益率2.78%
ROE2.46%
PER (TTM)49.4
予想PER13.66
PEG0.47
EPS$2.90
52週レンジ$66.57 – $211.00
アナリスト目標株価$153.25
アナリスト評価4.3 / 5

データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。

沿革

近日公開このセクションは現在準備中です。近日公開予定です。

業界での地位

近日公開このセクションは現在準備中です。近日公開予定です。